M-3554

N/A

Report date: 2024/10/16 20:01:12
First In Class

Base Information

Drug NameM-3554
Drug Alias NameM-3554M3554
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload
Mechanisms of ActionAnti-GD2DNA topoisomerase I inhibitors
TargetsDisialoganglioside GD2DNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesGermany +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck KGaA, Darmstadt, Germany
China Registration ClassN/A

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyEmd Serono Research & Development Institute Inc
Inactive CompaniesMerck KGaA, Darmstadt, Germany
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A